Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation

Takehiko Mori, Jun Kato, Akiko Yamane, Masatoshi Sakurai, Sumiko Kohashi, Taku Kikuchi, Yukako Ono, Shinichiro Okamoto

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

In a previous study, we noted wide inter-individual variability in drug interactions between voriconazole and tacrolimus, but that analysis did not take into account the routes of administration. In the present study, we analyzed interactions between these two drugs when both agents were administered orally after allogeneic hematopoietic stem cell transplantation (HSCT); the effect of plasma voriconazole levels on the magnitude of the drug interaction was also examined. Twenty-five allogeneic HSCT recipients were evaluated. Trough concentrations of tacrolimus were measured prior to, and periodically for 7-10 days after, initiating voriconazole (400 mg/day) to determine the concentration/dose (C/D) ratio of tacrolimus. The median C/D ratio of tacrolimus increased significantly from 172.8 (range 28.6-1110.7) to 537.5 (range 127.8-1933.3) (ng/mL)/(mg/kg) (P\0.01) following initiation of voriconazole; the median increase was 138.8 % (range -32.0 to 685.7 %). The plasma concentration of voriconazole did not correlate with the increase of the tacrolimus C/D ratio (ρ = 0.16, P = 0.44). These results indicate that oral voriconazole has a significant drug interaction with oral tacrolimus with a wide inter-individual variability, which cannot be explained by the bioavailability of voriconazole. Other possible mechanisms should be explored in future studies.

Original languageEnglish
Pages (from-to)564-569
Number of pages6
JournalInternational Journal of Hematology
Volume95
Issue number5
DOIs
Publication statusPublished - 2012 May

Fingerprint

Hematopoietic Stem Cell Transplantation
Tacrolimus
Drug Interactions
Biological Availability
Voriconazole
Pharmaceutical Preparations

Keywords

  • Drug interaction
  • Hematopoietic stem cell transplantation
  • Tacrolimus
  • Voriconazole

ASJC Scopus subject areas

  • Hematology

Cite this

@article{d853fe314b154525a35013387ff59121,
title = "Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation",
abstract = "In a previous study, we noted wide inter-individual variability in drug interactions between voriconazole and tacrolimus, but that analysis did not take into account the routes of administration. In the present study, we analyzed interactions between these two drugs when both agents were administered orally after allogeneic hematopoietic stem cell transplantation (HSCT); the effect of plasma voriconazole levels on the magnitude of the drug interaction was also examined. Twenty-five allogeneic HSCT recipients were evaluated. Trough concentrations of tacrolimus were measured prior to, and periodically for 7-10 days after, initiating voriconazole (400 mg/day) to determine the concentration/dose (C/D) ratio of tacrolimus. The median C/D ratio of tacrolimus increased significantly from 172.8 (range 28.6-1110.7) to 537.5 (range 127.8-1933.3) (ng/mL)/(mg/kg) (P\0.01) following initiation of voriconazole; the median increase was 138.8 {\%} (range -32.0 to 685.7 {\%}). The plasma concentration of voriconazole did not correlate with the increase of the tacrolimus C/D ratio (ρ = 0.16, P = 0.44). These results indicate that oral voriconazole has a significant drug interaction with oral tacrolimus with a wide inter-individual variability, which cannot be explained by the bioavailability of voriconazole. Other possible mechanisms should be explored in future studies.",
keywords = "Drug interaction, Hematopoietic stem cell transplantation, Tacrolimus, Voriconazole",
author = "Takehiko Mori and Jun Kato and Akiko Yamane and Masatoshi Sakurai and Sumiko Kohashi and Taku Kikuchi and Yukako Ono and Shinichiro Okamoto",
year = "2012",
month = "5",
doi = "10.1007/s12185-012-1057-2",
language = "English",
volume = "95",
pages = "564--569",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation

AU - Mori, Takehiko

AU - Kato, Jun

AU - Yamane, Akiko

AU - Sakurai, Masatoshi

AU - Kohashi, Sumiko

AU - Kikuchi, Taku

AU - Ono, Yukako

AU - Okamoto, Shinichiro

PY - 2012/5

Y1 - 2012/5

N2 - In a previous study, we noted wide inter-individual variability in drug interactions between voriconazole and tacrolimus, but that analysis did not take into account the routes of administration. In the present study, we analyzed interactions between these two drugs when both agents were administered orally after allogeneic hematopoietic stem cell transplantation (HSCT); the effect of plasma voriconazole levels on the magnitude of the drug interaction was also examined. Twenty-five allogeneic HSCT recipients were evaluated. Trough concentrations of tacrolimus were measured prior to, and periodically for 7-10 days after, initiating voriconazole (400 mg/day) to determine the concentration/dose (C/D) ratio of tacrolimus. The median C/D ratio of tacrolimus increased significantly from 172.8 (range 28.6-1110.7) to 537.5 (range 127.8-1933.3) (ng/mL)/(mg/kg) (P\0.01) following initiation of voriconazole; the median increase was 138.8 % (range -32.0 to 685.7 %). The plasma concentration of voriconazole did not correlate with the increase of the tacrolimus C/D ratio (ρ = 0.16, P = 0.44). These results indicate that oral voriconazole has a significant drug interaction with oral tacrolimus with a wide inter-individual variability, which cannot be explained by the bioavailability of voriconazole. Other possible mechanisms should be explored in future studies.

AB - In a previous study, we noted wide inter-individual variability in drug interactions between voriconazole and tacrolimus, but that analysis did not take into account the routes of administration. In the present study, we analyzed interactions between these two drugs when both agents were administered orally after allogeneic hematopoietic stem cell transplantation (HSCT); the effect of plasma voriconazole levels on the magnitude of the drug interaction was also examined. Twenty-five allogeneic HSCT recipients were evaluated. Trough concentrations of tacrolimus were measured prior to, and periodically for 7-10 days after, initiating voriconazole (400 mg/day) to determine the concentration/dose (C/D) ratio of tacrolimus. The median C/D ratio of tacrolimus increased significantly from 172.8 (range 28.6-1110.7) to 537.5 (range 127.8-1933.3) (ng/mL)/(mg/kg) (P\0.01) following initiation of voriconazole; the median increase was 138.8 % (range -32.0 to 685.7 %). The plasma concentration of voriconazole did not correlate with the increase of the tacrolimus C/D ratio (ρ = 0.16, P = 0.44). These results indicate that oral voriconazole has a significant drug interaction with oral tacrolimus with a wide inter-individual variability, which cannot be explained by the bioavailability of voriconazole. Other possible mechanisms should be explored in future studies.

KW - Drug interaction

KW - Hematopoietic stem cell transplantation

KW - Tacrolimus

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=84862849999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862849999&partnerID=8YFLogxK

U2 - 10.1007/s12185-012-1057-2

DO - 10.1007/s12185-012-1057-2

M3 - Article

C2 - 22461034

AN - SCOPUS:84862849999

VL - 95

SP - 564

EP - 569

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -